PemCarbo + Pem only
Phase 3UNKNOWN 1 views this week 0 watching💤 Quiet
Interest: 36/100
36
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Non-small Cell Lung Cancer
Conditions
Non-small Cell Lung Cancer
Trial Timeline
Mar 1, 2012 → Nov 1, 2015
NCT ID
NCT01593293About PemCarbo + Pem only
PemCarbo + Pem only is a phase 3 stage product being developed by Eli Lilly for Non-small Cell Lung Cancer. The current trial status is unknown. This product is registered under clinical trial identifier NCT01593293. Target conditions include Non-small Cell Lung Cancer.
What happened to similar drugs?
20 of 20 similar drugs in Non-small Cell Lung Cancer were approved
Approved (20) Terminated (2) Active (0)
Hype Score Breakdown
Clinical
17
Activity
4
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01593293 | Phase 3 | UNKNOWN |
Competing Products
20 competing products in Non-small Cell Lung Cancer